Peptides having skin condition improving activity and uses thereof

Abstract

The present application relates to a peptide having skin condition-improving activity and its uses, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1, and a cosmetic composition for improving skin condition that contains the peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Description

[Technical Field]

[0001] The present application relates to a peptide having skin condition-improving activity and uses thereof. [Background technology]

[0002] Human skin undergoes constant changes, the most common of which are a decline in skin function and a loss of visual beauty due to aging. Aging causes wrinkles on the skin, and typical factors that contribute to wrinkle formation include exposure to ultraviolet light and a decrease in collagen biosynthesis. Skin aging can be broadly divided into intrinsic aging, which is caused by genetic factors, and extrinsic aging, which is caused by external environmental factors such as sunlight. It is known that extrinsic aging can be prevented, treated, or delayed by removing reactive oxygen species, promoting fibroblast proliferation, and stimulating collagen biosynthesis.

[0003] Collagen, a major component of the extracellular matrix, is the primary matrix protein produced by skin fibroblasts. Collagen forms most of the organic material in skin, tendons, bones, and teeth, with particularly high concentrations in bone and skin (dermis). Collagen decreases with age and photoaging due to UV exposure, which is known to be closely related to the formation of skin wrinkles. Collagen also plays an important role in wound healing, promoting collagen synthesis in damaged epithelium and enabling wounds to heal quickly and without scars. Furthermore, it has been reported that promoting collagen biosynthesis increases the density of the basal layer and other layers, thereby reducing the melanin pigment concentration per unit skin density, resulting in a lighter skin tone.

[0004] Under such technical background, various researches are being conducted to improve skin condition through mechanisms such as promoting collagen biosynthesis and increasing the proliferation and activity of fibroblasts (Korean Patent Registration No. 10-1813629), but the reality is that there are still some shortcomings. Summary of the Invention [Problem to be solved by the invention]

[0005] One embodiment is to provide a peptide consisting of the amino acid sequence of SEQ ID NO:1.

[0006] Another aspect of the present invention is to provide a composition for improving skin conditions, which comprises a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0007] Other objects and advantages of the present application will become more apparent from the following detailed description, taken in conjunction with the claims and drawings. Contents not described in this specification can be fully understood and inferred by those skilled in the art of the present application or a similar art, and therefore, the description thereof will be omitted. [Means for solving the problem]

[0008] Each description and embodiment disclosed in this application may be applied to each other description and embodiment. In other words, all combinations of various elements disclosed in this application belong to the scope of this application. In addition, the specific descriptions described below are not intended to limit the scope of this application.

[0009] One embodiment provides a peptide consisting of the amino acid sequence of SEQ ID NO:1.

[0010] The term "peptide" as used herein refers to a linear molecule formed by amino acid residues linked to each other by peptide bonds. The peptide can be prepared by chemical synthesis methods known to those skilled in the art, particularly solid-phase synthesis or liquid-phase synthesis (U.S. Patent No. 5,516,891). The present inventors have made extensive efforts to develop peptides with biologically effective activities, and have identified a peptide having the amino acid sequence of SEQ ID NO: 1. The biologically effective activities may include any one or more of the following: (a) promoting the proliferation of fibroblasts or keratinocytes; (b) increasing the expression of extracellular matrix components such as collagen type 1 (Col1a1), fibronectin, or elastin; (c) increasing the expression of skin barrier factors such as sirtuin-1 (SIRT-1) or aquaforin-3 (AQP3); and (d) inhibiting the death of fibroblasts or keratinocytes and reducing reactive oxygen species levels. Therefore, the peptide can be used to improve skin conditions or as an antioxidant.

[0011] The peptides may also be conjugated with protecting groups at the N- or C-terminus to achieve chemical stability, enhanced pharmacological properties (e.g., half-life, absorbency, potency, efficacy), altered specificity (e.g., a broader spectrum of biological activity), or reduced antigenicity. In one embodiment, the N-terminus of the peptide may be conjugated with any one protecting group selected from the group consisting of an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and polyethylene glycol (PEG); and / or the C-terminus of the peptide may be conjugated with any one protecting group selected from the group consisting of an amino group (-NH), a tertiary alkyl group, and an azide (-NHNH). Optionally, the peptide may further comprise a targeting sequence, a tag, a labeled residue, or a specifically engineered amino acid sequence to increase half-life or peptide stability.

[0012] The peptides are artificially synthesized or non-naturally occurring or engineered, and the term "non-naturally occurring or engineered" refers to a state in which the peptides are produced by artificial modification, rather than in the state in which they exist in nature. Here, the artificial modification can include artificially synthesizing an amino acid sequence by mimicking multiple amino acid structures, or engineering the peptides to obtain chemical stability, enhanced pharmacological properties, altered specificity, or reduced antigenicity, as described above.

[0013] The term "stability" as used herein may refer not only to in vivo stability, which protects the peptide from attack by in vivo proteolytic enzymes, but also to storage stability (eg, storage stability at room temperature).

[0014] Another aspect provides a cosmetic composition for improving skin conditions, which comprises a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0015] Among the terms or elements mentioned in the description of the peptide, the same as those already mentioned are as described above.

[0016] As used herein, the term "amelioration" can refer to any action that at least reduces the parameters of the alleviation or treatment of a condition, for example, the severity of symptoms.

[0017] The term "skin condition improvement" as used herein comprehensively refers to the process or effect of treating, reducing, or alleviating skin damage caused by intrinsic or extrinsic factors, and may be interpreted as, for example, wrinkle improvement, skin elasticity improvement, wound recovery, skin barrier strengthening, or skin aging inhibition, but is not limited to these.

[0018] Here, "wrinkle reduction," "skin elasticity improvement," and "wound recovery" may refer to any action that increases the total amount of extracellular matrix factors, including promoting collagen synthesis. Furthermore, "strengthening the skin barrier" may refer to strengthening the skin's natural functions of preventing leakage of moisture and nutrients from within the skin and preventing the penetration of harmful substances such as bacteria and viruses into the skin. Furthermore, "inhibiting skin aging" may refer to inhibiting declines in skin function, such as wrinkles, skin sagging, and loss of elasticity. Here, skin aging also refers to photoaging, for example, skin aging caused by ultraviolet rays.

[0019] Although conventional functional peptides have effective biological activities, they have drawbacks such as ineffective delivery to target tissues or cells due to their size or a short half-life, resulting in rapid disappearance in the body. In contrast, a cosmetic composition according to one embodiment contains a peptide consisting of 10 or fewer amino acids as an active ingredient, which provides excellent skin penetration and effectively improves skin condition when applied topically to the skin.

[0020] According to one embodiment, the peptide promoted the proliferation of fibroblasts or keratinocytes and increased the synthesis of extracellular matrix components and skin barrier factors. Furthermore, the peptide was shown to be able to restore the inhibited activity of fibroblasts and keratinocytes and enhance their antioxidant activity. Therefore, the peptide can be used as an active ingredient in cosmetic compositions for improving skin conditions.

[0021] The cosmetic composition may contain, but is not limited to, a cosmetically effective amount of the peptide; and / or a cosmetically acceptable carrier.

[0022] As used herein, the term "cosmetically effective amount" means an amount sufficient to achieve the skin condition improving effect of the cosmetic composition.

[0023] The weight ratio between the peptide and the cosmetically acceptable carrier may be, for example, 500:1 to 1:500. By way of example, the weight ratio may be, but is not limited to, 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2.

[0024] The cosmetic composition may be prepared in any formulation commonly prepared in the art, such as, but not limited to, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleanser, oil, powder foundation, emulsion foundation, wax foundation, spray, etc. For example, it may be prepared in the form of a softening lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, or powder.

[0025] When the cosmetic composition is in the form of a paste, cream, or gel, the carrier component may be animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, or the like.

[0026] When the cosmetic composition is in the form of a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder is used as a carrier component, and in the case of a spray, for example, a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether may be further included.

[0027] When the cosmetic composition is in the form of a solution or emulsion, a solvent, solubilizer, or emulsifier is used as a carrier component, and may include, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol fatty esters, polyethylene glycol, or sorbitan fatty acid esters.

[0028] When the cosmetic composition is in the form of a suspension, a liquid diluent such as water, ethanol, or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used as a carrier component.

[0029] When the cosmetic composition is in the form of a surfactant-containing cleanser, fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters may be used as carrier components.

[0030] To further improve skin penetration or stability, the peptide can be incorporated into nanosomes or nanoparticles. For example, the nanosomes can be prepared using lecithin as a raw material using a microfluidizer, and then incorporated into lecithin particles. Any known method can be used to prepare the nanosomes. The nanosome particle size is preferably 30 to 200 nm. Nanosome particle sizes less than 30 nm can penetrate the skin too quickly, resulting in side effects. Nanosome particle sizes greater than 200 nm can penetrate the skin too quickly, making it difficult to achieve the benefits of using the nanosome structure.

[0031] The components contained in the cosmetic composition include, in addition to the peptide as an active ingredient and a carrier component, components commonly used in cosmetic compositions, such as common adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0032] The content of the peptide as an active ingredient contained in the cosmetic composition is appropriately selected without limitation depending on the product form, desired use, etc., and may be added in an amount of, for example, 0.01 to 15 wt % of the total weight of the cosmetic composition. Also, for example, the cosmetic composition may contain the peptide in an amount of 1.0 to 3.0 wt %, preferably 2.0 to 3.0 wt %, based on the total weight of the cosmetic composition.

[0033] Yet another aspect provides a method for improving skin condition, comprising applying to the skin of an individual a cosmetic composition containing as an active ingredient a peptide having the amino acid sequence of SEQ ID NO: 1; and a use of the peptide having the amino acid sequence of SEQ ID NO: 1 for the manufacture of a composition for improving skin condition.

[0034] Among the terms and elements mentioned in the description of the cosmetic composition, the same as those already mentioned are as described above.

[0035] As used herein, the term "individual" refers to a subject in need of skin condition improvement, and more specifically refers to a mammal such as a human or a non-human primate, mouse, dog, cat, horse, or cow.

[0036] As used herein, the terms "apply," "administer," and "apply" are used interchangeably and may refer to causing at least partial localization of a composition according to an embodiment to a desired site, or to the placement of a composition according to an embodiment within an individual by a route of administration.

[0037] Yet another embodiment provides an antioxidant composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0038] Among the terms or elements mentioned in the description of the peptide, the same as those already mentioned are as described above.

[0039] The antioxidant composition may be in the form of a pharmaceutical composition, a quasi-drug composition, or a cosmetic composition. For example, the composition may be used as a cosmetic composition for improving skin conditions or a pharmaceutical composition for improving or treating the condition of a disease associated with skin damage.

[0040] According to one embodiment, the peptide has been shown to restore the inhibited activity of fibroblasts and keratinocytes and enhance their antioxidant activity, and therefore, the peptide can be used as an active ingredient in antioxidant compositions.

[0041] The antioxidant composition may be provided in the form of a pharmaceutical composition, for example, which may include, but is not limited to, a pharmaceutically effective amount of the peptide and / or a pharmaceutically acceptable carrier.

[0042] The term "pharmaceutical effective amount" as used herein may refer to an amount sufficient to achieve the efficacy of the pharmaceutical composition in preventing or treating diseases associated with skin damage.

[0043] The pharmaceutically acceptable carriers are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, saccharose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0044] The weight ratio between the peptide and the pharmaceutically acceptable carrier may be, for example, 500:1 to 1:500. By way of example, the weight ratio may be, but is not limited to, 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2.

[0045] The pharmaceutical composition may further contain, in addition to the above ingredients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc., but is not limited to these.

[0046] The pharmaceutical composition may be administered orally or parenterally, preferably parenterally. In the case of parenteral administration, it may be administered by intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, topical administration, transdermal administration, etc., but is not limited thereto.

[0047] The dosage of the pharmaceutical composition may be, but is not limited to, 0.0001 to 1000 μg (micrograms), 0.001 to 1000 μg, 0.01 to 1000 μg, 0.1 to 1000 μg, or 1.0 to 1000 μg per day, and may be variously prescribed depending on factors such as formulation method, administration route, age, weight, sex, pathological condition, diet of the patient, administration time, administration route, excretion rate, and reaction sensitivity.

[0048] The pharmaceutical composition may be prepared in a unit dose form or in a multi-dose container by formulating it with pharmaceutically acceptable carriers and / or excipients in a manner that can be easily carried out by a person skilled in the art to which the invention pertains.

[0049] The dosage form may be in the form of a solution, suspension or emulsion in an oily or aqueous medium, or in the form of an extract, powder, granules, tablet or capsule, and may further contain a dispersing agent and / or a stabilizing agent.

[0050] Yet another aspect provides a food composition for improving skin conditions, which comprises a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0051] Among the terms or elements mentioned in the description of the peptide, the same as those already mentioned are as described above.

[0052] The content of the peptide as an active ingredient contained in the food composition is appropriately selected without limitation depending on the food form, desired use, etc., and may be added at, for example, 0.01 to 15 wt% of the total food weight. For example, in the case of a health drink composition, the peptide may be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml. [Effects of the Invention]

[0053] According to one embodiment, the peptide promotes the proliferation of fibroblasts and keratinocytes and enhances the synthesis of extracellular matrix components and skin barrier factors, and can be applied to improve skin conditions, including wrinkle reduction, skin elasticity improvement, wound recovery, skin barrier strengthening, or skin aging inhibition.

[0054] According to one embodiment, the peptide can contribute to the recovery of skin damage caused by external environmental factors such as ultraviolet rays by restoring the inhibited activity of fibroblasts and keratinocytes and enhancing their antioxidant efficacy.

[0055] Therefore, the peptide according to one embodiment can be used as an active ingredient in a composition for improving skin condition or an antioxidant composition. [Brief explanation of the drawings]

[0056] [Figure 1]This shows the results of confirming the cell proliferation level based on changes in cell viability after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells. [Figure 2] This shows the results of confirming increased expression of extracellular matrix components Col1a1, fibronectin, and elastin after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells. [Figure 3] A peptide consisting of the amino acid sequence of SEQ ID NO: 1 was added to NIH3T3 cells, and the expression levels of extracellular matrix components were quantitatively evaluated. Figure 3A shows the results of confirming the expression levels of Col1a1, Figure 3B shows the results of confirming the expression levels of fibronectin, and Figure 3C shows the results of confirming the expression levels of elastin. [Figure 4] This shows the results of confirming increased expression of skin barrier factors SIRT-1 and AQP3 after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells. [Figure 5] A peptide consisting of the amino acid sequence of SEQ ID NO: 1 was added to HaCaT cells, and the expression level of skin barrier factors was quantitatively evaluated. Figure 5A shows the results of confirming the expression level of SIRT-1, and Figure 5B shows the results of confirming the expression level of AQP3. [Figure 6] The peptide consisting of the amino acid sequence of SEQ ID NO: 1 was added to NIH3T3 cells, and the inhibitory effect on the death of skin cells induced by UV irradiation was confirmed through viability evaluation. [Figure 7] The peptide consisting of the amino acid sequence of SEQ ID NO: 1 was added to HaCaT cells, and the inhibitory effect on the death of skin cells induced by UV irradiation was confirmed through viability evaluation. [Figure 8] This shows the results of quantitatively confirming the change in the level of reactive oxygen species increased by ultraviolet light after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells. [Figure 9]This is the result of quantitatively confirming the change in the level of reactive oxygen species increased by ultraviolet light after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells. DETAILED DESCRIPTION OF THE INVENTION

[0057] The present invention will be described in more detail below with reference to examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

[0058] Example 1. Synthesis of peptides The peptide having the amino acid sequence of SEQ ID NO: 1 in Table 1 was synthesized using an automated peptide synthesizer (Milligen 9050, Millipore, USA), and the synthesized peptide was purified and separated using C18 reverse-phase high-performance liquid chromatography (HPLC) (Waters Associates, USA) on an ACQUITY UPLC BEH300 C18 column (2.1 mm ∘ 100 mm, 1.7 μm, Waters Co., USA).

[0059] [Table 1]

[0060] Example 2. Confirmation of the effect of promoting proliferation of skin cells In this example, the effect of the peptide according to one example on the proliferation of skin cells was confirmed by evaluating changes in the viability of NIH3T3 cells, which are mouse fibroblasts.

[0061] Specifically, NIH3T3 cells were cultured in a 96-well plate at 1x10 4After seeding at a density of 1000 cells / well, the cells were cultured for 24 hours. The cells were then washed once with serum-free DMEM media, and 200 μL of the serum-free medium was added with 50 μM or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1. The mixture was then cultured for 72 hours in a CO2 incubator at 37°C. The culture was then washed twice with PBS, and MTT solution was added to each well at a concentration of 0.5 mg / mL. The plate was then protected from light and cultured for 4 hours in a CO2 incubator at 37°C. The absorbance was measured at 540 nm using a microplate reader (Molecular Devices, USA).

[0062] As a result, as shown in FIG. 1, it was confirmed that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 promoted the proliferation of fibroblasts.

[0063] Example 3. Confirmation of wrinkle improvement and elasticity improvement effects In this example, the expression levels of collagen type 1 (Col1a1), fibronectin, and elastin, which are known to be components of the dermis, were evaluated to confirm the effect of the peptide according to one embodiment on improving intrinsic skin aging, including wrinkle improvement and elasticity enhancement.

[0064] Specifically, NIH3T3 cells were cultured in a 6-well plate at 3 x 10 5After seeding at a density of 1000 cells / well, the cells were cultured for 24 hours. After washing the cells once with serum-free DMEM media, 1 mL of the medium was supplemented with 10 μM or 50 μM of a peptide consisting of the amino acid sequence of SEQ ID NO: 1. The cells were then cultured in a CO2 incubator at 37°C for 24 hours. The cultures were then washed twice with PBS, and RNA was isolated from the cultures using Easy Blue (Intron, Cat. No.: 17061, Korea). The isolated RNA was reverse transcribed using an RT kit (Enzynomics, Cat. No.: RT200, Korea) to synthesize the respective cDNAs. Polymerase chain reaction (PCR) was then performed using 1 μg of the synthesized cDNA and primers for Col1a1, fibronectin, or elastin using a PCR kit (Enzynomics, Cat. No.: P581T, Korea). Meanwhile, in this example, the control group was an untreated group, and the positive control group was a group to which TGF-β1 was added. The nucleotide sequences of the primers used in this example are as shown in Table 2 below.

[0065] [Table 2]

[0066] As a result, as shown in Figures 2 and 3, it was confirmed that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 increased the expression of extracellular matrix components Col1a1, fibronectin, and elastin.

[0067] Example 4. Confirmation of skin barrier strengthening effect In this example, the expression levels of sirtuin-1 (SIRT-1) or aquaforin-3 (AQP3) were evaluated to confirm the effect of a peptide according to one example on strengthening the skin barrier.

[0068] Specifically, 3 x 10 HaCaT cells were plated in a 6-well plate. 5 The cells were seeded at a density of 1000 cells / well and cultured for 24 hours. After washing the cells once with serum-free DMEM media, 50 μM or 100 μM of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was added to 1 mL of the medium and cultured in a CO2 incubator at 37°C for 24 hours. The culture was then washed twice with PBS and RNA was isolated from the culture using Easy Blue (IntRON, Cat. No.: 17061, Korea). The isolated RNA was reverse transcribed using an RT kit (Enzynomics, Cat. No.: RT200, Korea) to synthesize the respective cDNAs. Polymerase chain reaction (PCR) was then performed using 1 μg of the synthesized cDNA, primers for SIRT-1 or AQP3, and a PCR kit (Enzynomics, Cat. No.: P581T, Korea). Meanwhile, in this example, an untreated group was used as a control group, and an EGF-added group was used as a positive control group. The nucleotide sequences of the primers used in this example are as shown in Table 3 below.

[0069] [Table 3]

[0070] As a result, as shown in Figures 4 and 5, it was confirmed that the expression of skin barrier factors SIRT-1 and AQP3 was increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. From the above results, it was found that the peptide according to one embodiment contributes to strengthening the skin barrier and skin anti-aging by increasing the skin barrier factors.

[0071] Example 5. Confirmation of the inhibitory effect on UV-induced skin cell death In this example, the effect of a peptide according to one embodiment on the inhibition of UV-induced death of skin cells or cell recovery was confirmed by evaluating changes in the survival rate of skin cells whose death was induced by UV irradiation.

[0072] Specifically, NIH3T3 or HaCaT cells were cultured in a 96-well plate at 1 x 10 4 After seeding at a density of 100 cells / well, the cells were cultured for 24 hours. The cells were then washed once with serum-free DMEM media, and 200 μL of the culture medium was dispensed with 50 μM or 100 μM of a peptide consisting of the amino acid sequence of SEQ ID NO: 1. The culture medium containing the peptide was cultured for 1 hour in a CO2 incubator at 37°C, transferred to an e-tube, mixed with 100 μl of PBS, and dispensed into well plates. Subsequently, a UV irradiator (VILBER LOURMAT, Cat No.: 3102-BSU, France) was used to irradiate NIH3T3 cells with 6 J / cm. 2 HaCaT cells were exposed to 15 mJ / cm of ultraviolet light. 2 The wells were irradiated with UV light for 10 min. Thereafter, the PBS in the well plate was removed, and MTT (Sigma, Cat. No.: M2003, USA) solution was dispensed into each well at 0.5 mg / ml and cultured in a CO2 incubator at 37°C for 72 hours. The absorbance of the culture was then measured at 540 nm using a microplate reader (Molecular Devices, USA). In this example, an untreated group was used as the control group, and a group containing Trolox (Trolox) was used as the positive control group.

[0073] As a result, as shown in Figures 6 and 7, it was confirmed that the cell viability of fibroblasts and keratinocytes, which had been reduced by UV irradiation, was restored by the peptide having the amino acid sequence of SEQ ID NO: 1. From the above results, it was found that the peptide according to one embodiment contributes to the inhibition of UV-induced death of skin cells.

[0074] Example 6: Confirmation of the effect of reducing reactive oxygen species increased by ultraviolet rays In this example, the effect of a peptide according to one embodiment on the antioxidant effect in damaged skin cells was confirmed by evaluating changes in the level of reactive oxygen species in skin cells that increased due to UV irradiation.

[0075] Specifically, 5 x 10 NIH3T3 or HaCaT cells were cultured in a 6-well plate. 5 After seeding at a density of 1000 cells / well, the cells were cultured for 24 hours. After that, the cells were washed once with serum-free DMEM media, and then 50 μM or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into 1 mL of the medium, and this was cultured for 1 hour in a CO2 incubator at 37°C. After that, the culture was transferred to an e-tube, mixed with 1 mL of PBS, and dispensed into a well plate. Then, using a UV irradiator (VILBER LOURMAT, Cat No.: 3102-BSU, France), NIH3T3 cells were exposed to 6 J / cm 2 HaCaT cells were exposed to ultraviolet light at 15 J / cm 2 The wells were then irradiated with UV light for 10 min. After removing the PBS from the well plate, 900 μL of the culture medium containing the peptide was added and incubated in a CO2 incubator at 37°C for 24 hours. The cultures were then treated with 10 μM of DCFG-DA (2',7'-dichlorofluorescin diacetate), wrapped in foil, and incubated in a CO2 incubator at 37°C for 30 minutes. The wells were then washed twice with PBS and treated with 500 μL of 1× trypsin / EDTA to obtain cells, which were then centrifuged. The centrifuged cells were washed with PBS and then measured for FL1 fluorescence intensity using flow cytometry (FACS, BD, USA). In this example, the control group was an untreated group, the comparative group was a group exposed to UV light only, and the positive control group was a group containing Trolox (Trolox).

[0076] As a result, as shown in Figures 8 and 9, it was confirmed that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 reduces the reactive oxygen levels in fibroblasts and keratinocytes that are increased by UV irradiation. From the above results, it was found that the peptide according to one embodiment contributes to the antioxidant effect on skin cells induced by UV rays.

[0077] Dosage Form Example 1. Production of Peptide Nanosomes 50 mg of the peptide from Example 1 was dissolved in 500 ml of distilled water with thorough stirring. The resulting solution was mixed with 5 g of lecithin, 0.3 ml of sodium oleate, 50 ml of ethanol, and a small amount of oil, and then the mixture was adjusted to 1 L with distilled water. The mixture was then emulsified under high pressure in a microfluidizer to produce peptide nanosomes with a size of approximately 100 nm.

[0078] Dosage form example 2: Softening lotion A softening lotion containing a peptide according to one embodiment and having the following composition was prepared using a method known in the art.

[0079] [Table 4]

[0080] Dosage form example 3: Nutritious cream A nourishing cream containing a peptide according to one embodiment and having the following composition was prepared using a method known in the art.

[0081] [Table 5]

[0082] Dosage form example 4: Nutritious lotion A nutritious lotion containing a peptide according to one embodiment and having the following composition was prepared using a method known in the art.

[0083] [Table 6]

[0084] Dosage form example 5. Essence An essence containing a peptide according to one embodiment and having the following composition was prepared using a method known in the art.

[0085] [Table 7]

[0086] The above description of the present invention is for illustrative purposes only, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. Therefore, it should be understood that the above-described embodiments are illustrative in all respects and are not limiting.

Claims

1. A peptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. 2. The peptide of claim 1, wherein the N-terminus of the peptide is bound to any one protecting group selected from the group consisting of an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and polyethylene glycol (PEG).

3. The C-terminus of the peptide is an amino group (-NH 2 ), tertiary alkyl groups and azides (-NHNH 2 2. The peptide of claim 1, wherein the peptide is bound to any one of the protecting groups selected from the group consisting of:

4. The peptide of claim 1, wherein the peptide exhibits one or more of the following properties: (a) promoting the proliferation of fibroblasts or keratinocytes; (b) Increased expression of extracellular matrix components such as collagen type 1 (Col1a1), fibronectin, or elastin; (c) Enhanced expression of skin barrier factors sirtuin-1 (SIRT-1) or aquaforin-3 (AQP3); and (d) Inhibition of fibroblast or keratinocyte death and reduction of reactive oxygen levels.

5. A cosmetic composition for improving skin conditions, comprising the peptide according to any one of claims 1 to 4 as an active ingredient.

6. The cosmetic composition according to claim 5 , wherein the peptide is formulated in the form of nanosomes.

7. The cosmetic composition according to claim 5 , wherein the improvement of skin condition is wrinkle improvement, improvement of skin elasticity, wound recovery, strengthening of skin barrier, or inhibition of skin aging.

8. The cosmetic composition according to claim 7, wherein the skin aging is skin aging caused by ultraviolet rays.

Images